Ongoing uncertainty about prices will deter new drug launches in Canada
Further delays in access or complete denials of access to innovative drugs will hurt even more Canadians with unmet or poorly met health needs that could be helped by these medicines.
Health Minister Jean-Yves Duclos speaks at an Aug. 23 press conference in Ottawa. Canada’s attractiveness as a marketplace for new medicines has already diminished as a result of uncertainty about the PMPRB changes, write Nigel Rawson and Brett Skinner. The Hill Times photograph by Andrew Meade